Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide

  • J. MirroJr.
  • W. Crom
  • J. Belt
  • M. Schell
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)


While the outcome for children with acute lymphocytic leukemia (ALL) has improved as a result of increased dose intensity, the same improvement has not occurred in acute myeloid leukemia (AML). Although approximately 85% of children with AML achieve a complete remission (CR), the majority ultimately relapse and die of their disease [1–5]. Although bone marrow transplant (BMT) offers better disease control, patient selection and the timing of transplantation remains controversial [6–8]. Furthermore, because of the risk of early death and the development of graftversus-host disease, clinical trials have not clearly demonstrated that BMT is the treatment of choice for AML in the first CR [9].


Acute Myeloid Leukemia Clin Oncol Cytosine Arabinoside Acute Nonlymphocytic Leukemia Relapse Acute Myeloid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weinstein HJ, Mayer RJ, Rosenthal DS et al. (1983) Chemotherapy for acute myeloge- 12. nous leukemia in children and adults: VAPA update. Blood 62: 315–319PubMedGoogle Scholar
  2. 2.
    Buckley JD, Lampkin BC, Nesbit ME et al. (1989) Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 17: 382–390PubMedCrossRefGoogle Scholar
  3. 3.
    Steuber CP, Civin C, Krischer J et al. (1991) A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 9: 247–258PubMedGoogle Scholar
  4. 4.
    Creutzig U, Ritter J, Riehm H et al. (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German Cooperative Study AML-BFM-78. Blood 65: 298–304PubMedGoogle Scholar
  5. 5.
    Kalwinsky D, Mirro J, Schell M et al. (1988) Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol 6: 1134–1143PubMedGoogle Scholar
  6. 6.
    Raimondi SC, Kalwinsky DK, Hayashi Yet al. (1989) The cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 40: 13–27PubMedCrossRefGoogle Scholar
  7. 7.
    Kalwinsky DK, Raimondi S, Schell MJ et al. (1990) Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 8: 75–83PubMedGoogle Scholar
  8. 8.
    Grier HE, Gelber RD, Camitta BM et al. (1987) Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 5: 1026–1032PubMedGoogle Scholar
  9. 9.
    Dahl GV, Kalwinsky DK, Mirro J et al. (1990) Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 8: 295–303PubMedGoogle Scholar
  10. 10.
    Liliemark JO, Plunkett W, Dixon DO (1985) Relationship of 1–3-D-arabinofuranosylcytosine in plasma to 1–3-D-arabinofuranosylcytosine 5’-triphosphate levels in leukemic cells during treatment with high-dose 113-D-arabinofuranosylcytosine. Cancer Res 45: 5952–5957PubMedGoogle Scholar
  11. 11.
    Rustum YM, Lawrence DD, Priore RL et al. (1986) Relationship between plasma pharmacokinetic parameters of arabinosylcytosine ( ARAC) intracellular ARA-CTP, and toxicity of acute nonlymphocytic leukemia patients to treatment with high dose ARAC. Am Soc Clin Oncol 5: 164–171Google Scholar
  12. 12.
    Bertino JR (1987) Blood levels of chemotherapeutic agents and clinical outcome. J Clin Oncol 5: 996–997PubMedGoogle Scholar
  13. 13.
    Rodman JR, Abromowitch M, Sinkule JA et al. (1987) Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J Clin Oncol 5: 1007–1014PubMedGoogle Scholar
  14. 14.
    Preisler HD, Rustum YM, Azarnia N et al. (1987) Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother Pharmacol 19: 69–74PubMedCrossRefGoogle Scholar
  15. 15.
    Plunkett W, Iacoboni S, Estey E et al. (1985) Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 3: 20–30Google Scholar
  16. 16.
    Karp JE, Donehower RC, Dole GB et al. (1987) Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1–13-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood 69: 1134–1140PubMedGoogle Scholar
  17. 17.
    Hande KR, Wedlund PJ, Noone RM et al. (1984) Pharmacokinetics of high-dose etoposide (VP-16–213) administered to cancer patients. Cancer Res 44: 379–382PubMedGoogle Scholar
  18. 18.
    Ehninger G, Proksch B, Wanner T et al. (1990) Cytosine arabinoside uptake and cytosine arabinoside triphosphate formation by leukemic blast cells is inhibited by etoposide and teniposide. Blood 76 (10) [Suppl 1]: 266 aGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. MirroJr.
    • 1
  • W. Crom
    • 1
  • J. Belt
    • 1
  • M. Schell
    • 1
  1. 1.Departments of Hematology-Oncology, Pharmacokinetics, Biochemical Pharmacology, and BiostatisticsSt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations